PglL ComP O-OTase Glycosylation of Streptococcus Capsular Polysaccharides

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current O-oligosaccharyltransferases (OTases) are unable to efficiently attach capsular polysaccharides containing glucose at the reducing end to protein carriers, limiting their application in vaccine development, particularly for Streptococcus species.

Innovation Solution

The use of PglL ComP O-oligosaccharyltransferase to glycosylate a full-length pilin-like protein ComP with bacterial capsular polysaccharides containing glucose at the reducing end, enabling the generation of glycoproteins suitable for vaccine applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If current O-oligosaccharyltransferases are used to attach capsular polysaccharides to protein carriers, then the enzyme can perform its standard glycosylation function, but it cannot efficiently attach capsular polysaccharides containing glucose at the reducing end

Engineering Contradiction:
Improveability to attach different types of capsular polysaccharidesVSAvoidefficiency of polysaccharide attachment
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent modifies the chemical structure of the capsular polysaccharide by replacing the glucose residue at the reducing end with a non-reducing sugar analog (such as 2-deoxy-2,3-didehydroglucose or other analogs). This parameter change in the sugar structure allows the polysaccharide to be efficiently attached to protein carriers by O-oligosaccharyltransferases, overcoming the enzyme's inability to process native glucose-containing polysaccharides while maintaining immunogenicity for vaccine applications

Inventive Principle:
Principle #35Parameter changes

2Productivity

If chemical methods are used to attach polysaccharides to proteins, then attachment can be achieved, but the process is complex and less efficient

Engineering Contradiction:
Improveattachment efficiencyVSAvoidcomplexity of attachment process
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent replaces complex chemical conjugation methods with a biological enzymatic system. By using O-oligosaccharyltransferases to catalyze the attachment of modified capsular polysaccharides to protein carriers, the process achieves high efficiency and specificity without requiring complex chemical reagents, multiple reaction steps, or extensive purification procedures associated with chemical methods

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

PglL ComP efficiently attaches capsular polysaccharides to protein carriers, generating immune responses in mice and providing a basis for the development of more effective vaccines against Streptococcus, including Streptococcus pneumoniae.

Implementation Method 1

PglL ComP O-oligosaccharyltransferase efficiently attaches capsular polysaccharides to protein carriers

Methodology Applied
Scientific EffectO-oligosaccharyltransferase catalysis: Enzyme

Data Source

PatentEP3262077B1Acinetobacter o-oligosaccharyltransferases and uses thereof
Publication Date: 2025.06.04 VAXNEWMO LLC
  • EP3262077B1 patent drawingFigure 1A~1D
  • EP3262077B1 patent drawingFigure 2A~2B
  • EP3262077B1 patent drawingFigure 3A~3C

AI summary

The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pilin-like protein ComP using a Pg1LComP O-OTase. Uses of glycoproteins synthesized by glycosylating Com P using Pg1LComP O-OTase, particularly for the preparation of vaccines and the like, including a vaccine to Streptococcus, is also provided.